Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEU-HF: JK07 in Adults With Chronic Heart Failure
NCT06369298Phase 2Active, not recruiting
- Sponsor
- Salubris Biotherapeutics
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of JK07 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by Salubris Biotherapeutics. Primary endpoints: Safety at 52 weeks and Efficacy at 26 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
JK07
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06369298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369298.